Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries-Reference-Cited by-同舟云学术

Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries

Published:2017-06-08 Issue: Volume:8 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Kawalec Paweł,Stawowczyk Ewa,Tesar Tomas,Skoupa Jana,Turcu-Stiolica Adina,Dimitrova Maria,Petrova Guenka I.,Rugaja Zinta,Männik Agnes,Harsanyi Andras,Draganic Pero

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference25 articles.

1. Budget impact analysis of biosimilar infliximab for the treatment of crohn's disease in six central eastern European countries;Brodszky;Value Health,2014

2. A budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia;Brodszky;Expert Rev. Pharmacoecon. Outcomes Res.,2016

3. Patent expiry dates for best-selling biological;Derbyshire;Gene. Biosimilars Initiat. J.,2015

4. 32/2004. (IV. 26.) ESzCsM Decree, Concerning the Reimbursement of Medicinal Products2017

5. European Public Assessment Reports2017

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Format for presenting a clinical case in the scientific journal;Heart, Vessels and Transplantation;2024-08-15

2. Cost-Effectiveness of Biosimilars vs Leflunomide in Patients With Rheumatoid Arthritis;JAMA Network Open;2024-06-26

3. Policy measures and instruments used in European countries to increase biosimilar uptake: a systematic review;Frontiers in Public Health;2024-02-28

4. Unveiling the Biosimilar Paradox of Oncologists’ Perceptions and Hesitations in South Korea: A Web-Based Survey Study;BioDrugs;2024-01-12

5. How Managed Entry Agreements Influence the Patients’ Affordability to Biological Medicines—Bulgarian Example;Healthcare;2023-08-30